Another petition for reimb listing of TNBC drug 'Trodelvy'
By Eo, Yun-Ho | translator Kang, Shin-Kook
24.05.07 05:31:42
°¡³ª´Ù¶ó
0
In January, 50,000 people have agreed to a posting on Korea¡¯s petition platform
After clearing the review by the Cancer Diseases Review Committee, no updates for five months
¡ãGilead Science Korea¡¯s Trodelvy (Sacituzumab govitecan).
There is now yet another petition requesting reimbursement listing of the new breast cancer drug 'Trodelvy'.
There was already a previous posting with 50,000 votes in January of last year. It appears that another petition was posted because it has been three months without any updates.
A petitioner, who introduced themselves on the national petition platform on May 2nd as a stage 4 triple-negative breast cancer (TNBC) patient, pleaded for support in need of Trodelvy reimbursement, stating, "The tumor is growing too fast. I earnestly request the community to participate to extend the treatment option to me as a stage 4 patient."
There has not been any updates regardi
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)